Source: Eur Respir Rev, 27 (148) 180033; 10.1183/16000617.0033-2018
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Chandak Upagupta, Chiko Shimbori, Rahmah Alsilmi, Martin Kolb. Matrix abnormalities in pulmonary fibrosis. Eur Respir Rev, 27 (148) 180033; 10.1183/16000617.0033-2018

Member's Comments

No comment yet.

Related content which might interest you: Metalloproteinases in idiopathic pulmonary fibrosis Source: Eur Respir J 2011; 38: 1461-1467 Year: 2011 Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Matrix metalloproteinases in pulmonary fibrosis Source: Annual Congress 2013 –Regulation of lung inflammation and repair by proteolysis Year: 2013 Epithelium involvement and remodeling of interstitium in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pulmonary fibrosis Source: Eur Respir Mon; 2009: 45: 46–53 Year: 2009 Extracellular matrix profile of lung in idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary hypertension in idiopathic pulmonary fibrosis: Utility of HRCT Source: International Congress 2014 – COPD and PAH related imaging Year: 2014 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Modelling pulmonary fibrosis Source: Annual Congress 2012 - PG4 Experimental models for respiratory medicine: strengths and limitations Year: 2012 Right ventricular dysfunction in pulmonary hypertension with combined pulmonary fibrosis and emphysema syndrome Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Changes in the small airways in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 Ectopic subpleural fat deposition in idiopathic pulmonary fibrosis correlates with radiographic extension of fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir Mon 2012; 57: 148-160 Year: 2012 Right ventricular REMODELING in idiopathic pulmonary fibrosis with or without pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015